Cardiovascular Safety and Superiority of Anti-Obesity Medications

Muath Alobaida,1,&ast; Abdullah Alrumayh,1,&ast; Ayodipupo S Oguntade,2 Faez Al-Amodi,3 Mwango Bwalya3 1Department of Basic Sciences, Prince Sultan bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Kingdom of Saudi Arabia; 2Nuffield Department of Population...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alobaida M, Alrumayh A, Oguntade AS, Al-Amodi F, Bwalya M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	anti-obesity medication cardiovascular diseases cardiovascular outcome trials type 2 diabetes mellitus obesity obesity therapy Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5146ded483e84cf48f6788278e5f7e76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5146ded483e84cf48f6788278e5f7e76
record_format	dspace
spelling	oai:doaj.org-article:5146ded483e84cf48f6788278e5f7e762021-12-02T16:39:55ZCardiovascular Safety and Superiority of Anti-Obesity Medications1178-7007https://doaj.org/article/5146ded483e84cf48f6788278e5f7e762021-07-01T00:00:00Zhttps://www.dovepress.com/cardiovascular-safety-and-superiority-of-anti-obesity-medications-peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Muath Alobaida,1,&ast; Abdullah Alrumayh,1,&ast; Ayodipupo S Oguntade,2 Faez Al-Amodi,3 Mwango Bwalya3 1Department of Basic Sciences, Prince Sultan bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Kingdom of Saudi Arabia; 2Nuffield Department of Population Health, University of Oxford, Oxford, UK; 3Institute of Cardiovascular Science, University College London, London, UK&ast;These authors contributed equally to this workCorrespondence: Muath Alobaida; Abdullah AlrumayhDepartment of Basic Science, Prince Sultan bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Kingdom of Saudi ArabiaEmail malobaida1@ksu.edu.sa; aalrumayh@ksu.edu.saAbstract: Over the past few decades, several anti-obesity medications have demonstrated an association with adverse cardiovascular outcomes, leading to their market withdrawal. This has caused researchers to investigate the cardiovascular safety of such medications in cardiovascular outcome trials. However, the data from these trials are limited, and their outcomes are not promising. Therefore, the aim of this review is to provide an overview of the current and past Food and Drug Administration-approved medications for weight loss, including novel diabetes medications (glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) and non-diabetes medications, and to highlight the current designs of cardiovascular outcome trials and their importance in the evaluation of the overall safety concerns associated with these anti-obesity medications. The limitations of the trials and opportunities for improvement were also evaluated. Finally, we also briefly describe cardiovascular safety and risks in this review.Keywords: anti-obesity medication, cardiovascular diseases, cardiovascular outcome trials, type 2 diabetes mellitus, obesity, obesity therapyAlobaida MAlrumayh AOguntade ASAl-Amodi FBwalya MDove Medical Pressarticleanti-obesity medicationcardiovascular diseasescardiovascular outcome trialstype 2 diabetes mellitusobesityobesity therapySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 3199-3208 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-obesity medication cardiovascular diseases cardiovascular outcome trials type 2 diabetes mellitus obesity obesity therapy Specialties of internal medicine RC581-951
spellingShingle	anti-obesity medication cardiovascular diseases cardiovascular outcome trials type 2 diabetes mellitus obesity obesity therapy Specialties of internal medicine RC581-951 Alobaida M Alrumayh A Oguntade AS Al-Amodi F Bwalya M Cardiovascular Safety and Superiority of Anti-Obesity Medications
description	Muath Alobaida,1,&ast; Abdullah Alrumayh,1,&ast; Ayodipupo S Oguntade,2 Faez Al-Amodi,3 Mwango Bwalya3 1Department of Basic Sciences, Prince Sultan bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Kingdom of Saudi Arabia; 2Nuffield Department of Population Health, University of Oxford, Oxford, UK; 3Institute of Cardiovascular Science, University College London, London, UK&ast;These authors contributed equally to this workCorrespondence: Muath Alobaida; Abdullah AlrumayhDepartment of Basic Science, Prince Sultan bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Kingdom of Saudi ArabiaEmail malobaida1@ksu.edu.sa; aalrumayh@ksu.edu.saAbstract: Over the past few decades, several anti-obesity medications have demonstrated an association with adverse cardiovascular outcomes, leading to their market withdrawal. This has caused researchers to investigate the cardiovascular safety of such medications in cardiovascular outcome trials. However, the data from these trials are limited, and their outcomes are not promising. Therefore, the aim of this review is to provide an overview of the current and past Food and Drug Administration-approved medications for weight loss, including novel diabetes medications (glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) and non-diabetes medications, and to highlight the current designs of cardiovascular outcome trials and their importance in the evaluation of the overall safety concerns associated with these anti-obesity medications. The limitations of the trials and opportunities for improvement were also evaluated. Finally, we also briefly describe cardiovascular safety and risks in this review.Keywords: anti-obesity medication, cardiovascular diseases, cardiovascular outcome trials, type 2 diabetes mellitus, obesity, obesity therapy
format	article
author	Alobaida M Alrumayh A Oguntade AS Al-Amodi F Bwalya M
author_facet	Alobaida M Alrumayh A Oguntade AS Al-Amodi F Bwalya M
author_sort	Alobaida M
title	Cardiovascular Safety and Superiority of Anti-Obesity Medications
title_short	Cardiovascular Safety and Superiority of Anti-Obesity Medications
title_full	Cardiovascular Safety and Superiority of Anti-Obesity Medications
title_fullStr	Cardiovascular Safety and Superiority of Anti-Obesity Medications
title_full_unstemmed	Cardiovascular Safety and Superiority of Anti-Obesity Medications
title_sort	cardiovascular safety and superiority of anti-obesity medications
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/5146ded483e84cf48f6788278e5f7e76
work_keys_str_mv	AT alobaidam cardiovascularsafetyandsuperiorityofantiobesitymedications AT alrumayha cardiovascularsafetyandsuperiorityofantiobesitymedications AT oguntadeas cardiovascularsafetyandsuperiorityofantiobesitymedications AT alamodif cardiovascularsafetyandsuperiorityofantiobesitymedications AT bwalyam cardiovascularsafetyandsuperiorityofantiobesitymedications
_version_	1718383572667072512

Cardiovascular Safety and Superiority of Anti-Obesity Medications

Ejemplares similares